Pediatrics

IBS in pediatric patients has not been studied much, but new data reveals a possible treatment.

Post-COVID-19 conditions were more common in unvaccinated children than in children who had received at least 1 dose of a COVID-19 vaccine.

Data was presented at the 44th National Association of Pediatric Nurse Practitioners Conference regarding the effectiveness of vaccines and antivirals in preventing life threatening conditions.

At the 44th National Association of Pediatric Nurse Practitioners Conference, a session presented data explaining why teenagers with T1D are at high risk for developing anorexia and bulimia.

As more and more states legalize recreational marijuana, caregivers need to be vigilant about keeping products out of the reach of children.

The drug, called Leniolisib, is the first and only treatment approved in the United States for APDS, a rare primary immunodeficiency.

Pharmacogenetic testing and therapeutic drug monitoring are feasible in the inpatient psychiatric treatment setting.

All children included in the analysis with presymptomatic SMA achieved swallowing, oral nutrition, and airway protection outcomes.

Dupilumab met both its primary and key secondary endpoints in a phase 3 trial, demonstrating efficacy as a potential treatment for atopic hand and foot dermatitis.

Evkeeza, which treats a rare form of high cholesterol, is now approved for patients as young of 5 years.

Voxzogo is already available for patients over 5 years with a genetic cause of dwarfism. The PDUFA date is set for Oct. 21, 2023, and will potentially expand the drug to children 5 and under.

With nearly 250,000 kindergarten age children not receiving their recommended vaccines, pediatric health care providers search for solutions.

The vaccine was 73.2% effective in children aged 6 months to 4 years when administered during the Omicron-dominant phase.

The updated vaccine schedule includes vaccinations for influenza, pneumococcal disease, measles, mumps, and rubella (MMR) and COVID-19.

The FDA has granted Priority Review for linclotide (LINZESS; Ironwood Pharmaceuticals) for treating functional constipation in pediatric patients.

The FDA has updated its compounding guidelines for licensed pharmacies, hospitals, and health systems.

Results of a phase 3 clinical trial represent another avenue of treatment for children and adolescents living with type 2 diabetes.

A 2021 morbidity study found that COVID-19 was among the leading causes of death in children and young people.

Odactra, a tablet for treating pediatric house dust mite-induced allergic rhinitis, has been approved by the US Food and Drug Administration for patients aged 12 to 17 years.

A study aims to quantify the burden of current childhood asthma in the United States in association with smoke from indoor gas stoves.

In a report from the Centers for Disease Control and Prevention, it was shown that symptoms and hospitalizations associated with influenza this season are higher among children than adults.

A follow-up of a trial cohort showed that children aged 5 years born to pregnant smokers had improved airway function when vitamin C supplementation was administered during pregnancy compared to placebo.

A recent study found a rise in the prevalence of antipsychotic prescriptions among pediatric patients and noted which antipsychotics were most commonly used for specific indications.

The updates include new recommendations for COVID-19 and pneumococcal vaccines.

Childhood vaccinations took a downturn during the pandemic. Now is the time to get them done and pharmacists can help.

A recent study found that the risk of cardiovascular diseases was not significantly greater in patients taking medications for attention-deficit/hyperactivity disorder (ADHD), but investigators were not able to rule out a mild risk increase.

Pharmacists can play an important role in patients’ wellness journeys.

Careful thought and adjustments are required to avoid exceeding the maximum recommended amount.

Patients with a history of multisystem inflammatory syndrome in children (MIS-C) completed a questionnaire about adverse reactions following COVID-19 vaccination, and no serious adverse events were recorded.

The US Food Administration has agreed to review an application for nirsevimab (Beyfortus; AstraZeneca and Sanofi) to protect infants against RSV.